首页> 外文期刊>Recent patents on endocrine, metabolic & immune drug discovery. >Incretins Yesterday, Pleiotropic Gastrointestinal Hormones Today: Glucagon-Like Peptide-1 (GLP-1) and Glucose-Dependent Insulinotropic Polypeptide (GIP)
【24h】

Incretins Yesterday, Pleiotropic Gastrointestinal Hormones Today: Glucagon-Like Peptide-1 (GLP-1) and Glucose-Dependent Insulinotropic Polypeptide (GIP)

机译:昨天的肠促胰岛素,今天的促胃肠道激素:胰高血糖素样肽1(GLP-1)和葡萄糖依赖性促胰岛素多肽(GIP)

获取原文
获取原文并翻译 | 示例
       

摘要

Incretins, which are insulinotropic gastrointestinal hormones, are produced mainly in K and L cells of the small intestine under the influence of nutritional stimuli. The best known incretins are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These hormones perform several functions: they stimulate insulin secretion in the pancreatic beta cells; they inhibit glucagon release from the alpha cells of the pancreas (GIP not in humans); they slow down gastric emptying and may directly suppress appetite; and, moreover, they indirectly increase peripheral glucose tolerance/insulin sensitivity. The insulinotropic and glucagonostatic effects of GLP-1 are glucose dependent. The incretins also have numerous other properties which are still being discovered and introduced in different branches of medicine. The patents mentioned in this work concern the use of incretins in diabetology, cardiology, gastroenterology and nuclear medicine. The pleiotropic effects of incretins offer therapeutic possibilities in numerous fields of medicine.
机译:肠促胰岛素是促胰岛素的胃肠激素,主要在营养刺激的作用下在小肠的K和L细胞中产生。最著名的肠降血糖素是胰高血糖素样肽1(GLP-1)和葡萄糖依赖性促胰岛素多肽(GIP)。这些激素具有多种功能:它们刺激胰腺β细胞中的胰岛素分泌。它们抑制胰高血糖素从胰腺的α细胞释放(GIP不适用于人类);它们会减慢胃排空的速度,并可能直接抑制食欲;而且,它们间接增加了外周葡萄糖耐量/胰岛素敏感性。 GLP-1的促胰岛素和促胰岛激素作用是葡萄糖依赖性的。肠降血糖素还具有许多其他性质,其仍在不同医学分支中被发现和引入。这项工作中提到的专利涉及肠降血糖素在糖尿病,心脏病,肠胃病和核医学中的用途。肠降血糖素的多效性为许多医学领域提供了治疗可能性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号